Login to Your Account

Stock Dives 28%

Oxigene Restructures, Future of Lung Cancer Drug Uncertain

By Catherine Shaffer

Friday, September 2, 2011
Oxigene Inc. reported a radical restructuring to conserve resources and focus on earlier stage programs. The company will conclude its Phase II trial of Zybrestat in non-small-cell lung cancer (NSCLC), and defer initiation of Phase III registration studies of the drug in anaplastic thyroid cancer due to lack of funding.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription